Effects of Medicinal Cannabis in the Treatment of Autism Spectrum Disorder Associated with Generalized Anxiety
PDF (Português (Brasil))

Keywords

Cannabis
Autism Spectrum Disorder
Anxiety Disorders

How to Cite

Silva, M. M. da, Nahmias, S. de S. V., Gomes, M. R. G., Sena, K. G. S. de, Moura, K. A. de, Bezerra, T. A., Borges, A. de S., Rocha, T. L., Queiroz, A. de P., Maciel, R. de P., Silva, L. F., Pereira, L. de O. C., Maslinkiewicz, A., & Braga, L. E. G. (2025). Effects of Medicinal Cannabis in the Treatment of Autism Spectrum Disorder Associated with Generalized Anxiety. Brazilian Journal of Implantology and Health Sciences, 7(3), 468–479. https://doi.org/10.36557/2674-8169.2025v7n3p468-479

Abstract

Introduction: Medicinal cannabis has emerged as a potential therapeutic approach for several neuropsychiatric conditions, including autism spectrum disorder (ASD) associated with generalized anxiety. ASD is characterized by impairments in communication and social interaction, often accompanied by high levels of anxiety, significantly impacting patients' quality of life. The endocannabinoid system has been implicated in the regulation of mood and stress response, suggesting that cannabinoids, especially cannabidiol (CBD), may have therapeutic effects in this context. Methodology: An integrative literature review was conducted using the Virtual Health Library (VHL) and PubMed databases. Nineteen articles published between 2000 and 2025, in Portuguese, English and Spanish, were selected. Inclusion criteria included studies that addressed the use of medicinal cannabis in ASD and generalized anxiety, while incomplete articles or articles published outside the established period were excluded. Results and discussion: The studies analyzed indicated that medicinal cannabis, particularly CBD, can reduce anxiety symptoms and improve social interaction in individuals with ASD. The proposed mechanisms involve modulation of the endocannabinoid system, influencing neurotransmission and inflammatory processes. However, variability in dosage and formulation of extracts poses a challenge for standardizing treatment. Although the results are promising, the methodological heterogeneity of the studies and the scarcity of randomized clinical trials limit the generalization of the findings. Conclusion: Medicinal cannabis emerges as a potentially effective therapeutic alternative for individuals with ASD associated with generalized anxiety, especially for those who do not respond adequately to conventional therapies. However, additional research, including robust clinical trials, is needed to establish standardized protocols and evaluate the long-term safety and efficacy of this intervention.

https://doi.org/10.36557/2674-8169.2025v7n3p468-479
PDF (Português (Brasil))

References

AGARWAL, Rumi et al. Current state of evidence of cannabis utilization for treatment of autism spectrum disorders. Bmc Psychiatry, [S.L.], v. 19, n. 1, p. 1-10, 29 out. 2019. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s12888-019-2259-4.

AMIN, Md Ruhul et al. Pharmacology of Medical Cannabis. Advances In Experimental Medicine And Biology, [S.L.], v. 5, n. 1, p. 151-165, nov. 2019. Springer International Publishing. http://dx.doi.org/10.1007/978-3-030-21737-2_8.

CAMMÀ, Guido et al. Therapeutic potential of minor cannabinoids in psychiatric disorders: a systematic review. European Neuropsychopharmacology, [S.L.], v. 91, n. 8, p. 9-24, fev. 2025. Elsevier BV. http://dx.doi.org/10.1016/j.euroneuro.2024.10.006.

DAMMANN, Inga et al. Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review. Pharmacopsychiatry, [S.L.], v. 57, n. 03, p. 115-132, 24 jan. 2024. Georg Thieme Verlag KG. http://dx.doi.org/10.1055/a-2228-6118.

EBBERT, Jon O. et al. Medical Cannabis. Mayo Clinic Proceedings, [S.L.], v. 93, n. 12, p. 1842-1847, dez. 2018. Elsevier BV. http://dx.doi.org/10.1016/j.mayocp.2018.09.005.

ERRIDGE, Simon et al. Clinical outcome analysis of patients with autism spectrum disorder: analysis from the uk medical cannabis registry. Therapeutic Advances In Psychopharmacology, [S.L.], v. 12, n. 1, p. 1-12, jan. 2022. SAGE Publications. http://dx.doi.org/10.1177/20451253221116240.

FREITAS, Francisca Dias de et al. El papel de los cannabinoides en los trastornos del neurodesarrollo de niños y adolescentes. Revista de Neurología, [S.L.], v. 75, n. 07, p. 97-189, 30 ago. 2022. IMR Press. http://dx.doi.org/10.33588/rn.7507.2022123.

GLENNY, Laura et al. Medical cannabis. International Journal Of Palliative Nursing, [S.L.], v. 30, n. 6, p. 263-263, 2 jun. 2024. Mark Allen Group. http://dx.doi.org/10.12968/ijpn.2024.30.6.263.

HILL, Matthew N. et al. The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses. Psychological Medicine, [S.L.], v. 53, n. 15, p. 7006-7024, 6 set. 2023. Cambridge University Press (CUP). http://dx.doi.org/10.1017/s0033291723002465.

HOLDMAN, Richard et al. Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications. Cannabis And Cannabinoid Research, [S.L.], v. 7, n. 4, p. 451-463, 1 ago. 2022. Mary Ann Liebert Inc. http://dx.doi.org/10.1089/can.2020.0154.

KHAN, Rabia et al. The therapeutic role of Cannabidiol in mental health: a systematic review. Journal Of Cannabis Research, [S.L.], v. 2, n. 1, p. 1-21, 2 jan. 2020. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s42238-019-0012-y.

KIRKLAND, Anna E. et al. A scoping review of the use of cannabidiol in psychiatric disorders. Psychiatry Research, [S.L.], v. 308, n. 8, p. 1-24, fev. 2022. Elsevier BV. http://dx.doi.org/10.1016/j.psychres.2021.114347.

LEGARE, Christopher A. et al. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals. Pharmacology, [S.L.], v. 107, n. 3-4, p. 131-149, dez. 2022. S. Karger AG. http://dx.doi.org/10.1159/000521683.

MÜLLER-VAHL, Kirsten R. et al. Cannabinoids in the Treatment of Selected Mental Illnesses: practical approach and overview of the literature. Pharmacopsychiatry, [S.L.], v. 57, n. 03, p. 104-114, 1 mar. 2024. Georg Thieme Verlag KG. http://dx.doi.org/10.1055/a-2256-0098.

PISANTI, S. et al. Medical Cannabis: a plurimillennial history of an evergreen. Journal Of Cellular Physiology, [S.L.], v. 234, n. 6, p. 8342-8351, 11 nov. 2018. Wiley. http://dx.doi.org/10.1002/jcp.27725.

PONTON, Juliana Andrea et al. A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: a case report. Journal Of Medical Case Reports, [S.L.], v. 14, n. 1, p. 1-7, 22 set. 2020. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s13256-020-02478-7.

RICE, Lauren J. et al. Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review. European Child & Adolescent Psychiatry, [S.L.], v. 33, n. 2, p. 505-526, 3 mar. 2023. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s00787-023-02169-w.

SILVA JUNIOR, Estácio Amaro da et al. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. Trends In Psychiatry And Psychotherapy, [S.L.], v. 5, n. 5, p. 1-9, set. 2024. EDITORA SCIENTIFIC. http://dx.doi.org/10.47626/2237-6089-2021-0396.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2025 Maycon Marwin da Silva, Suane de Santana Vaz Nahmias, Maria Rafaella Guedes Gomes, Kettilly Geisane Silva de Sena, Katarina Anunciada de Moura, Tamires Almeida Bezerra, Alex de Souza Borges, Thiara Lopes Rocha, Amanda de Paula Queiroz, Regiane de Paula Maciel, Lucas Freitas Silva, Lívia de Oliveira Contini Pereira, Alexandre Maslinkiewicz, Luís Eduardo Gomes Braga

Downloads

Download data is not yet available.